Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Innostem Bio is currently managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions involve 2 distinct examiners but are both assigned to 1 distinct art unit. This concentration suggests that the company's current biological filings are being evaluated by a specific technical group within the patent office. Because all pending matters are within 1 distinct art unit, the company can expect a relatively uniform application of examination guidelines for its biotechnology applications. This environment helps in predicting the types of rejections or requirements that might arise.
The busiest examiner for this portfolio is DRISCOLL, LORA E BARNHART, who is responsible for 1 pending office action. This represents a portion of the 2 pending office actions currently active. Having 2 distinct examiners means the company is interacting with multiple individuals, yet the 1 distinct art unit ensures they remain within the same administrative framework. This balance allows the applicant to gain insights from different reviewers while benefiting from the specialized knowledge of the single art unit in the Biotechnology & Pharmaceuticals field. The outcome of these interactions will be critical for the company's position.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| §112 only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DRISCOLL, LORA E BARNHART | 1 | 32.0% | +20.0% |
| PAULUS, ERIN VIRGINIA | 1 | 21.1% | +93.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18568851 | METHOD FOR MANUFACTURING PERIPHERAL NERVE-MIMICKING MICROTISSUE AND USES THEREOF | PAULUS, ERIN VIRGINIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18290155 | METHOD FOR ISOLATING AND CULTURING TISSUE-RESIDENT UPAR+/NESTIN+ STEM CELLS, AND USE THEREOF | DRISCOLL, LORA E BARNHART | — |
| 18568851 | METHOD FOR MANUFACTURING PERIPHERAL NERVE-MIMICKING MICROTISSUE AND USES THEREOF | PAULUS, ERIN VIRGINIA | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18290155 | METHOD FOR ISOLATING AND CULTURING TISSUE-RESIDENT UPAR+/NESTIN+ STEM CELLS, AND USE THEREOF | DRISCOLL, LORA E BARNHART | — | §112 | Non-Final OA | — | Pending | Sep 22, 2024 |
| 18568851 | METHOD FOR MANUFACTURING PERIPHERAL NERVE-MIMICKING MICROTISSUE AND USES THEREOF | PAULUS, ERIN VIRGINIA | 1631 | §103 | Final Rejection | — | Pending | Dec 11, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial